Abbott Laboratories (NYSE:ABT) – William Blair increased their Q4 2017 earnings estimates for shares of Abbott Laboratories in a report released on Wednesday. William Blair analyst M. Kaczor now anticipates that the healthcare product maker will post earnings of $0.73 per share for the quarter, up from their previous estimate of $0.72.

Several other research firms also recently issued reports on ABT. Citigroup Inc. reaffirmed a “neutral” rating on shares of Abbott Laboratories in a report on Thursday. Barclays PLC reaffirmed an “overweight” rating on shares of Abbott Laboratories in a report on Thursday. BMO Capital Markets reaffirmed a “market perform” rating on shares of Abbott Laboratories in a report on Thursday. Stifel Nicolaus upped their price objective on shares of Abbott Laboratories from $58.00 to $63.00 and gave the stock a “buy” rating in a report on Thursday. Finally, Royal Bank Of Canada upped their price objective on shares of Abbott Laboratories from $55.00 to $60.00 and gave the stock an “outperform” rating in a report on Thursday. Seven investment analysts have rated the stock with a hold rating and ten have issued a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus target price of $56.81.

WARNING: This piece was originally reported by American Banking News and is the sole property of of American Banking News. If you are accessing this piece on another domain, it was stolen and republished in violation of US & international trademark and copyright law. The legal version of this piece can be read at https://www.americanbankingnews.com/2017/10/23/q4-2017-eps-estimates-for-abbott-laboratories-lifted-by-william-blair-abt.html.

Shares of Abbott Laboratories (ABT) opened at 56.32 on Monday. Abbott Laboratories has a 1-year low of $37.38 and a 1-year high of $56.60. The stock has a market cap of $97.85 billion, a P/E ratio of 78.88 and a beta of 1.06. The company’s 50-day moving average is $53.27 and its 200 day moving average is $48.51.

Abbott Laboratories (NYSE:ABT) last released its quarterly earnings results on Wednesday, October 18th. The healthcare product maker reported $0.66 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.65 by $0.01. Abbott Laboratories had a net margin of 8.37% and a return on equity of 14.50%. The firm had revenue of $6.83 billion for the quarter, compared to the consensus estimate of $6.72 billion. During the same quarter in the previous year, the firm posted $0.59 EPS. The firm’s quarterly revenue was up 28.8% on a year-over-year basis.

Several hedge funds have recently made changes to their positions in the company. Farmers & Merchants Investments Inc. raised its stake in shares of Abbott Laboratories by 5.7% in the 3rd quarter. Farmers & Merchants Investments Inc. now owns 124,219 shares of the healthcare product maker’s stock valued at $6,628,000 after buying an additional 6,729 shares in the last quarter. Town & Country Bank & Trust CO dba First Bankers Trust CO raised its stake in shares of Abbott Laboratories by 2.2% in the 3rd quarter. Town & Country Bank & Trust CO dba First Bankers Trust CO now owns 51,119 shares of the healthcare product maker’s stock valued at $2,728,000 after buying an additional 1,090 shares in the last quarter. Tributary Capital Management LLC acquired a new position in shares of Abbott Laboratories in the 3rd quarter valued at $106,000. Bristlecone Advisors LLC acquired a new position in shares of Abbott Laboratories in the 3rd quarter valued at $212,000. Finally, First United Bank Trust raised its stake in shares of Abbott Laboratories by 40.4% in the 3rd quarter. First United Bank Trust now owns 8,256 shares of the healthcare product maker’s stock valued at $441,000 after buying an additional 2,375 shares in the last quarter. Institutional investors own 71.45% of the company’s stock.

In other news, insider Brian J. Blaser sold 15,000 shares of the stock in a transaction on Thursday, July 27th. The shares were sold at an average price of $50.00, for a total value of $750,000.00. Following the completion of the transaction, the insider now owns 143,154 shares in the company, valued at approximately $7,157,700. The sale was disclosed in a filing with the SEC, which is available at this link. Also, insider Stephen R. Fussell sold 196,550 shares of the stock in a transaction on Wednesday, August 16th. The shares were sold at an average price of $49.50, for a total transaction of $9,729,225.00. Following the completion of the transaction, the insider now owns 221,488 shares of the company’s stock, valued at approximately $10,963,656. The disclosure for this sale can be found here. In the last 90 days, insiders sold 333,310 shares of company stock valued at $16,857,255. Corporate insiders own 0.76% of the company’s stock.

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, November 15th. Stockholders of record on Friday, October 13th will be paid a $0.265 dividend. This represents a $1.06 dividend on an annualized basis and a dividend yield of 1.88%. The ex-dividend date is Thursday, October 12th. Abbott Laboratories’s dividend payout ratio is 83.47%.

About Abbott Laboratories

Abbott Laboratories is engaged in the discovery, development, manufacture and sale of a range of healthcare products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. Its Established Pharmaceutical Products include a range of branded generic pharmaceuticals manufactured around the world and marketed and sold outside the United States.

Earnings History and Estimates for Abbott Laboratories (NYSE:ABT)

Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.